CF
INMB icon

Corebridge Financial’s INmune Bio INMB Stock Holding History

Corebridge Financial’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,627
Closed -$51.8K – 1332
2025
Q1 		$51.8K Sell
6,627
-99
-1% -$786 ﹤0.01% 2726
2024
Q4 		$31.4K Sell
6,726
-507
-7% -$2.64K ﹤0.01% 2913
2024
Q3 		$39K Buy
7,233
+666
+10% +$4.74K ﹤0.01% 2920
2024
Q2 		$58K Buy
+6,567
New +$64.7K ﹤0.01% 2852

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Corebridge Financial's INMB Position: Q2 2025 in Review

Corebridge Financial sold out of INmune Bio (INMB) in Q2 2025, closing a stake of 6,627 shares — an estimated $51.8K sold.

Corebridge Financial first reported a position in INMB in Q2 2024 and held it in 4 quarters. The position peaked at $58K in Q2 2024. 79 funds tracked by Wall St. Rank hold INMB as of Q2 2025.

  • Corebridge Financial reported no remaining INmune Bio position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 6,627 INmune Bio shares in Q2 2025, an estimated $51.8K.
  • Corebridge Financial first reported a position in INmune Bio in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's INmune Bio position peaked at $58K in Q2 2024.
  • 79 funds tracked by Wall St. Rank held INmune Bio as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.